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Summary
Background Lower-respiratory-tract infection is one of the most common acute illnesses managed in primary care. 
Few placebo-controlled studies of antibiotics have been done, and overall eﬀ ectiveness (particularly in subgroups 
such as older people) is debated. We aimed to compare the beneﬁ ts and harms of amoxicillin for acute lower-
respiratory-tract infection with those of placebo both overall and in patients aged 60 years or older.
Methods Patients older than 18 years with acute lower-respiratory-tract infections (cough of ≤28 days’ duration) in 
whom pneumonia was not suspected were randomly assigned (1:1) to either amoxicillin (1 g three times daily for 
7 days) or placebo by computer-generated random numbers. Our primary outcome was duration of symptoms rated 
“moderately bad” or worse. Secondary outcomes were symptom severity in days 2–4 and new or worsening symptoms. 
Investigators and patients were masked to treatment allocation. This trial is registered with EudraCT (2007-001586-15), 
UKCRN Portfolio (ID 4175), ISRCTN (52261229), and FWO (G.0274.08N).
Findings 1038 patients were assigned to the amoxicillin group and 1023 to the placebo group. Neither duration of 
symptoms rated “moderately bad” or worse (hazard ratio 1·06, 95% CI 0·96–1·18; p=0·229) nor mean symptom 
severity (1·69 with placebo vs 1·62 with amoxicillin; diﬀ erence –0·07 [95% CI –0·15 to 0·007]; p=0·074) diﬀ ered 
signiﬁ cantly between groups. New or worsening symptoms were signiﬁ cantly less common in the amoxicillin group 
than in the placebo group (162 [15·9%] of 1021 patients vs 194 [19·3%] of 1006; p=0·043; number needed to treat 30). 
Cases of nausea, rash, or diarrhoea were signiﬁ cantly more common in the amoxicillin group than in the placebo group 
(number needed to harm 21, 95% CI 11–174; p=0·025), and one case of anaphylaxis was noted with amoxicillin. Two 
patients in the placebo group and one in the amoxicillin group needed to be admitted to hospital; no study-related 
deaths were noted. We noted no evidence of selective beneﬁ t in patients aged 60 years or older (n=595).
Interpretation When pneumonia is not suspected clinically, amoxicillin provides little beneﬁ t for acute lower-
respiratory-tract infection in primary care both overall and in patients aged 60 years or more, and causes slight harms.
Funding European Commission Framework Programme 6, UK National Institute for Health Research, Barcelona 
Ciberde Enfermedades Respiratorias, and Research Foundation Flanders.
Introduction
Acute uncomplicated lower-respiratory-tract infection is 
the most common acute illness managed in primary care 
in developed countries; most patients receive antibiotics, 
even in low-antibiotic-prescribing countries.1–4 Many 
patients worry about severe symptoms,5 and clinicians 
are keen to appropriately treat acute bacterial infections 
to avoid medicolegal consequences, provide symptomatic 
beneﬁ t, and avoid complications (especially community-
acquired pneumonia).3,6–8 However, the pre scription of 
antibiotics has costs, including the purchase of the drugs 
themselves, dispensing costs, and costs asso ciated with 
increased reconsultation because of the med icalisation 
of self-limiting illness.9,10 Primary care prescribing of 
antibiotics is one of the main drivers of resistance, which 
is also a major threat.11
Consensus opinion has been to restrict antibiotic use 
in acute lower-respiratory-tract infections.12–15 However, a 
Cochrane review16 of the use of antibiotics for acute 
bronchitis showed moderate beneﬁ ts—eg, a number 
needed to treat of 6 for cough, almost halving the number 
of patients not improving, and no signiﬁ cant short-term 
harms. Thus, the debate about the balance of beneﬁ t and 
harm continues, especially because of the scarcity of data 
from placebo-controlled trials for important symptomatic 
outcomes for patients, such as the number of days 
feeling ill (fewer than 500 patients were included in the 
Cochrane review16). Which sub groups of patients will 
probably beneﬁ t from treatment, and particularly the 
eﬀ ects in older patients (in whom most complications 
occur), are also debated.3 Most clinicians tend to prescribe 
antibiotics for older people with severe illness and major 
comorbidities, but the role of drugs in ﬁ tter older patients 
is unclear.
We aimed to provide robust estimates of the beneﬁ ts and 
harms of amoxicillin in acute uncomplicated community-
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acquired lower-respiratory-tract infections, particularly for 
important symptomatic outcomes for patients, both 
overall and in older patients.
Methods
Study design and patients
We did a parallel, randomised, placebo-controlled trial. 
Patients were recruited between Nov 15, 2007, and 
April 14, 2010 (the predeﬁ ned cutoﬀ  deﬁ ned by the trial 
steering committee), at primary care practices in 
16 networks in 12 European countries (Belgium, Eng land, 
France, Germany, Italy, the Netherlands, Poland, Slovakia, 
Slovenia, Spain, Sweden, and Wales). Recruit ment rates 
were low because of time pressures during the ﬁ rst winter 
season, so further networks in France, Poland, Slovakia, 
and Slovenia were recruited; these networks joined 
during the winter of 2008–09. Additionally, two of the 
original networks had diﬃ  culty obtaining approval from 
the competent authority, so did not start recruting until 
the second winter. Trial procedures were all shown to be 
feasible and thus no changes in documentation or process 
were necessary.
Eligible patients were aged 18 years or older and 
consulting for the ﬁ rst time with either an acute cough 
(≤28 days’ duration) as their main symptom, for which 
non-infective diagnoses were judged very unlikely, or an 
illness in which cough was not the most prominent 
symptom but the clinician thought acute lower-re-
spiratory-tract infection the most probably diagnosis.
We excluded patients in whom the initial clinical 
diagnosis was community-acquired pneumonia17 (ie, 
complicated lower-respiratory-tract infection) on the basis 
of focal chest signs (focal crepitations, bronchial breathing) 
and systemic features (high fever, vomiting, severe diar-
rhoea). We did not use a formal clinical prediction rule for 
the diagnosis of pneumonia because of the absence of 
consensus about which rule to use.18–21 Patients were 
excluded pragmatically when the working diagnosis was 
cough of non-infective cause (eg, pulmonary embolus, 
left ventricular failure, oesophageal reﬂ ux, allergy); anti-
biotics had been used in the previous month; they were 
unable to provide informed consent or complete a diary 
(eg, if they had dementia, psychosis, or severe depres-
sion); or they were pregnant, allergic to penicillin, or 
had immunological deﬁ ciencies. Previous diagnoses of 
asthma, chronic obstructive pulmonary disease, and 
other comorbid disorders were not exclusion criteria, and 
thus acute infective exacerbations were included.
The study was approved by ethics committees in all 
participating countries. The competent authority in each 
country also gave their approval. Patients who fulﬁ lled the 
inclusion criteria were given written and verbal information 
on the study and provided written informed consent.
Randomisation and masking
Trial drugs were block randomised by Scott Harris, a 
statistician in our research group who is independent of 
the GRACE consortium. The random code was sent as a 
password-protected list and as a hardcopy to the 
manufacturer, Almac (Armagh, UK). Both clinicians 
and patients were masked to the randomisation 
sequence, and all outcome data were gathered masked 
to allocation status. 
Almac prepared containers with the contents (amoxicillin 
or placebo) determined by a computer-generated random 
number list provided by a statistician who was independent 
of the trial statisticians. The amoxicillin and placebo were 
manufactured to be identical in appearance, taste, and 
texture. The random isation codes for amoxicillin or 
placebo were kept by the manufacturer and the designated 
pharmacist at the University Medical Center, Utrecht. A 
24 h unmasking service also had access to the list to break 
the code in an emergency. Unmasking was acceptable 
when requested by clinicians for clinical reasons, such as 
ad verse events—eg, anaphylaxis, hospital admission with 
life-threatening illness (such as severe sepsis, meningitis, 
severe pneumonia necessitating ad mission to intensive-
care unit), death.
Procedures
Patients were recruited consecutively by clinicians in 
each practice (to the extent possible within the time 
constraints of daily practice). Those who agreed to 
randomisation were allocated (1:1) to receive three times 
daily either 1 g amoxicillin or placebo for 7 days by the 
clinician, who dispensed sequentially numbered 
randomised containers. Recruiting health-care prof-
essionals had to keep non-recruitment logs and record 
reasons for not screening patients. The dose was based 
on a Monte Carlo simulation; we aimed to reach a 
minimum inhibitory concentration of roughly 1·5 mg/L 
to cover Haemophilus inﬂ uenzae and intermediately 
resistant pneumococci for 90% of the intended 
population (taking into account countries with high rates 
of antibiotic use and well documented pneumococcal 
resistance). We estimated that, to achieve bacterial 
eradication, concen trations needed to be higher than the 
minimum inhibitory concentration for at least 5 days. 
We chose a 7 day course for acceptability to clinicians and 
to allow for poor compliance.
The responsible clinician recorded comorbidities, 
clinical signs, and the severity of baseline symptoms 
reported by the patient on a case report form. Each 
symptom was rated as “no problem”, “mild problem”, 
“moderate problem”, or “severe problem”. Clinical 
characteristics were compared with a recent observational 
study1 that used the same clinical pro forma but was 
much less time intensive, and so recruited eligible 
patients more quickly.
After consultation with the responsible clinician, pa-
tients completed a daily symptom diary for the duration 
of the illness (to a maximum of 28 days). The diary items 
recorded the severity of cough, phlegm, shortness of 
breath, wheeze, blocked or runny nose, chest pain, 
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muscle aches, headaches, disturbed sleep, general 
feeling of being unwell, fever, and interference with 
normal activities. Each symptom was scored on a scale 
from 0 to 6 (0=no problem, 1=very little problem, 2=slight 
problem, 3=moderately bad, 4=bad, 5=very bad, 6=as bad 
as it could be). Patients also recorded non-respiratory 
symptoms, such as diarrhoea, skin rash, and vomiting. 
This diary has previously been val idated and is sensitive 
to change and internally reliable (Cronbach’s α 0·75).9,22 
All study materials were translated into relevant local 
languages. Back translations were checked to ensure 
consistency of meaning between networks.1
Members of the research team telephoned participants 
after 4 days to oﬀ er support and answer any questions 
about completion of the diary. If the diary was not 
returned after 4 weeks, we collected brief information 
with either a short questionnaire or a standardised 
telephone call about symptom duration and severity. 
Participating clinicians registered all contacts with 
patients for 4 weeks after the initial consultation, 
including referral to hospitals and out-of-hours contacts.
Outcomes
We speciﬁ ed three key outcomes, which were intended to 
capture important symptomatic outcomes for patients, 
before the trial. These outcomes did not change when 
the trial began. Our primary outcome was the duration of 
symptoms rated by patients as “moderately bad” or worse 
after initial presentation. We chose this endpoint because 
it was easy for patients and physicians to understand.
Symptom severity and new or worsening symptoms 
were secondary endpoints. Symptom severity was 
measured as the mean diary score for all symptoms 
during days 2–4 after the index consultation.9
We deﬁ ned new or worsening symptoms as a return to 
the physician with worsening symptoms, new symptoms, 
new signs, or illness necessitating admission to hospital 
within 4 weeks after the ﬁ rst consultation (established 
from reviews of patients’ notes).
Statistical analysis
For symptom duration and severity, our priority was to 
estimate the probable beneﬁ t of antibiotics. The null 
hypothesis was that antibiotics provide no beneﬁ t for 
important symptomatic outcomes for patients, neither 
overall nor for people aged 60 years or older. We assumed 
an α of 0·01 (for multiple outcomes), 80% power, and 
20% loss to follow-up, and estimated that 544 patients 
would be needed in each age group to detect a 
0·33 standardised diﬀ erence between groups (equivalent 
to 1·5 days of symptoms rated “mod erately bad”, or one 
patient in three rating the diary components “a slight 
problem” instead of “a moderately bad problem”). For the 
total cohort we estimated that 1110 patients overall would 
detect a 0·23 standardised diﬀ erence between groups, 
equivalent to a day of symp toms labelled “moderately 
bad”. Diﬀ erences much smaller than this cutoﬀ  are 
3108 patients agreed to random assignment
1047 patients ineligible
 33 allergic to penicillin
 13 had clinical pneumonia
 1001 chose not to be randomly assigned
1023 patients allocated to placebo
     82 did not take placebo
1038 patients allocated to 1 g amoxicillin 
 three times daily
     64 did not take amoxicillin
Symptoms recorded in 899 patientsSymptoms recorded in 908 patients
2061 patients randomly assigned
130 patients lost to follow-up 124 patients lost to follow-up
Figure 1: Trial proﬁ le
Amoxicillin Placebo
Women 624/1038 (60·1%) 600/1023 (58·7%)
Age (years) 48·6 (16·7) 49·3 (16·4)
Non-smoker (past or present) 477/1037 (46·0%) 483/1022 (47·3%)
Illness duration before index consultation (days) 9·5 (8·0) 9·3 (7·2)
Respiratory rate (breaths per min) 16·9 (3·3) 16·9 (3·3)
Body temperature (°C) 36·7 (3·3) 36·8 (3·3)
Lung disease* 163/1037 (15·7%) 147/1023 (14·4%)
Mean severity score (all symptoms)† 2·1 (0·5) 2·1 (0·5)
Mean severity score (cough)† 3·1 (0·7) 3·2 (0·7)
Sputum production 814/1036 (78·6%) 824/1021 (80·7%)
Discoloured sputum‡ 481/968 (49·7%) 468/957 (48·9%)
Data are n/N (%) or mean (SD). *Chronic obstructive pulmonary disease or asthma. †Severity of symptoms: 1=no 
problem; 2=mild problem; 3=moderate problem; 4=severe problem. ‡Green, yellow, or bloodstained.
Table 1: Baseline characteristics
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Figure 2: Kaplan-Meier estimates for duration of symptoms rated “moderately bad” or worse
Articles
126 www.thelancet.com/infection   Vol 13   February 2013
unlikely to be clinically signiﬁ cant.9 For new or worsening 
symptoms, we assumed an α of 0·05, 80% power, 5% 
loss to follow-up, and that 15% of patients suﬀ er new or 
worsening symptoms, and esti mated that 586 patients in 
each age group could detect a 50% reduction as a result 
of antibiotics, and a total cohort of 1500 could detect a 
33% reduction (ie, from 15% to 10%). Thus, our 
minimum sample size target was 586 patients in each 
age group and 1500 for the total cohort; our maximum 
target was 1500 patients in each age group.
We did all analyses masked to treatment allocation. 
We did not do an interim analysis. Subgroup analyses of 
patients aged 60 years or older were speciﬁ ed in 
advance. We decided to do a secondary analysis for 
patients aged 70 years or older after com pletion of data 
collection. We used linear regression models that 
controlled for the severity of baseline symptoms—
speciﬁ cally, Cox regression for the duration of symptoms 
allowing for censoring, simple linear regression for 
symptom severity, and logistic regression for 
deterioration of illness. We assessed any evidence of a 
diﬀ erence in beneﬁ t for patients aged 60 years or older 
versus the younger group by estimating interaction 
terms for each outcome. Separate estimates were made 
for participants aged 60 years or older and for those 
aged 70 years or older. Our primary analyses included 
patients for whom we had outcome data (ie, complete 
cases) on an intention-to-treat basis. We assessed the 
possible eﬀ ects of loss to follow-up by estimating the 
change in hazard ratio (HR) for several assumptions 
about resolution of symptoms in patients with missing 
data. Number needed to treat and number needed to 
harm were calculated. No per-protocol analysis was 
done. We checked that the groups were balanced by 
country, practice, and network. 
We used Stata (version 11.2) for all analyses. For 
interpretation we used a signiﬁ cance threshold of 5% for 
the primary outcome and 1% for the secondary outcomes 
to minimise the chance of type I error with multiple 
outcomes. The trial was registered with EudraCT 
(Eudract-CT 2007-001586-15) in November, 2007, and in 
January, 2009, we obtained an ISRCTN number 
(ISRCTN52261229). Trial procedures did not change 
between the two registrations.
Role of the funding source
The funding sources had no roles in data collection, 
analysis, or interpretation; report writing; or submission. 
PL, MM, and BS had full access to all the data in the 
study and take responsibility for the integrity of the data 
and the accuracy of the data analysis. All authors had 
responsibility for the ﬁ nal decision to submit for 
publication.
Results
3108 patients agreed to participate during recruitment; 
2061 were randomly assigned—1038 to the amoxicillin 
group and 1023 to the placebo group (ﬁ gure 1). 
Recruitment took more than 30 min. Because of time 
pressures during winter, not all potentially eligible 
patients were screened, and completion of non-
recruitment logs was poor (data not shown). Lack of time 
was the main reason given for not screening, and was 
reported by 44 (92%) of 48 health-care professionals. Only 
three (6%) health-care professionals reported that patients’ 
clinical state restricted recruitment. 595 (28·9%) of the 
trial population were aged 60 years or older; 310 (15·0%) 
had asthma or chronic obstructive pulmonary disease; 
and 1966 (95·8%) of 2052 had dyspnoea, sputum, or fever 
(nine patients had missing data). Table 1 shows the 
baseline clinical characteristics of the amoxicillin and 
placebo groups.
Symptom duration was documented in 1799 
(87·3%) partici pants and symptom severity in 
1789 (86·8%). New or worsening symptoms were 
measured in 2027 (98·3%) participants; 356 (17·6%) had 
new or worsening symptoms. 778 (92·4%) of 
842 participants in the amoxicillin group and 746 (90·1%) 
of 828 in the placebo group reported taking study drug at 
day 5 in their diaries (by which stage bacteria should have 
been eradicated).
Symptoms rated “moderately bad” or worse lasted a 
median of 6 days in the amoxicillin group (IQR 3–11) and 
7 days (4–14) in the placebo group; the diﬀ erence between 
Amoxicillin Placebo Odds ratio 
(95% CI)
p Number needed 
to treat (95% CI)
Whole cohort 162/1021 (15·9%) 194/1006 (19·3%) 0·79 (0·63 to 0·99) 0·043 30 (16 to 811)
Age 60 years or 
older
54/285 (18·9%) 58/299 (19·4%) 0·97 (0·64 to 1·47) 0·890 222 (17 to –15)
Age younger than 
60 years
108/736 (14·7%) 136/707 (19·2%) 0·72 (0·55 to 0·95) 0·021 22 (13 to 128)
Data are n/N (%) unless otherwise speciﬁ ed.
Table 4: Worsening of illness in the amoxicillin group versus placebo group
n Placebo Amoxicillin Diﬀ erence (95% CI) p 
Whole cohort 1789 1·69 (0·84) 1·62 (0·84) –0·07 (–0·15 to 0·007) 0·074
Age 60 years or older 547 1·50 (1·02) 1·47 (0·94) –0·03 (–0·17 to 0·11) 0·676
Age younger than 60 years 1242 1·78 (0·85) 1·69 (0·85) –0·08 (–0·18 to 0·01) 0·073
Data are mean (SD) unless otherwise speciﬁ ed. Each symptom was scored from 0 to 6 (0=no problem, 1=very little 
problem, 2=slight problem, 3=moderately bad, 4=bad, 5=very bad, 6=as bad as it could be).
Table 3: Mean symptom severity score on days 2–4 after consultation (controlling for baseline 
symptom severity) 
n Hazard ratio (95% CI) p
Whole cohort 1799 1·06 (0·96–1·18) 0·229
Age 60 years or older 550 0·95 (0·79–1·14) 0·555
Age younger than 60 years 1249 1·12 (0·98–1·24) 0·071
Table 2: Resolution of symptoms rated “moderately bad” or worse in 
amoxicillin group versus placebo group
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the groups was not signiﬁ cant (HR 1·06, 95% CI 
0·96–1·18; p=0·229; ﬁ gure 2, table 2, appendix). 
Duration of symptoms rated “moderately bad” or worse 
did not diﬀ er signiﬁ cantly between the older age group 
and the younger age group  (interaction term 0·86; 
p=0·116) and and no select ive beneﬁ t was noted in the 
older age group. Symptom severity did not diﬀ er between 
treatment groups (table 3), and no selective beneﬁ t was 
detected in the older age group (interaction term 0·06; 
p=0·47). In the 266 participants aged 70 years or older, 
the diﬀ erences between treatment groups for symptom 
severity (–0·04, 95% CI –0·21 to 0·12; p=0·614) and 
symptom duration (HR 0·96, 95% CI 0·94–1·16; 
p=0·432) were not signiﬁ cant (data not shown). Exclusion 
of patients with asthma or chronic obstructive pulmonary 
disease made little diﬀ erence to the estimates of duration 
of symptoms rated “moderately bad” or worse (HR 1·04).
Signiﬁ cantly fewer individuals experienced new or 
worsened symptoms in the amoxicillin group overall 
than in the placebo group (table 4), but the number 
needed to treat was high (30). No signiﬁ cant diﬀ erences 
were noted in the older age group. 
Controlling for network did not signiﬁ cantly aﬀ ect 
ﬁ ndings. Between groups, the HR for duration of 
symptoms was 1·06 (95% CI 0·96–1·18; p=0·229), 
diﬀ erence in symptom severity was –0·07 (–0·15 to 0·01; 
0·085), and odds ratio for new or worsening symptoms 
was 0·80 (0·63–1·02; 0·067).
Nausea, rash, or diarrhoea was recorded by 249 (28·7%) 
of 867 participants in the amoxicillin group and 206 (24·0%) 
of 860 in the placebo group (number needed to harm 21, 
95% CI 11–174; p=0·025). No study-related deaths were 
noted. Three patients (two in the placebo group and one 
in the amoxicillin group) were acutely admitted to 
hospital for respiratory or cardio vascular issues during 
the month after randomisation. One patient in the 
amoxicillin group had documented anaphylaxis.
Assumptions about missing study data did not 
signiﬁ cantly aﬀ ect our results and thus our inferences 
remain acceptable (table 5).
Discussion
To our knowledge, this trial is the largest multicentre 
randomised placebo-controlled study of antibiotics for 
acute, uncomplicated lower-respiratory-tract infection 
(panel). We noted that amoxicillin did not signiﬁ cantly 
reduce the duration of symptoms rated “moderately bad” 
or worse or symptom severity compared with placebo. 
Our cohort had similar clinical characteristics to the 
previous observational cohort recruited in these networks1 
and other cohorts of people with lower-respiratory-tract 
infections.1,9,27,28
The applicability of our ﬁ ndings is strengthened by 
the international nature of the trial and the broad, 
pragmatic inclusion criteria. These properties could 
mean that our population is heterogeneous, but such 
demographics represent the diagnostic realities of daily 
practice because no accepted diagnostic algorithm to 
identify patients with infection is available, and no 
universally agreed deﬁ nition exists for the diagnosis of 
uncomplicated lower-respiratory-tract infection.16 We used 
criteria consistent with consensus exercises29 and similar 
to those of previous pragmatic trials, large cohorts, and 
observational studies.1,28,30,31
Most patients in our study had acute cough with 
sputum. When we excluded key groups such as patients 
with asthma or chronic obstructive pulmonary disease or 
those aged 60 years or older, our results were little 
aﬀ ected, suggesting that our ﬁ ndings can probably be 
generalised to most patients with clinically deﬁ ned acute 
lower-respiratory-tract infection in primary care (where 
nearly all such infections are managed). Recruitment was 
slow, and feedback during and after the study clariﬁ ed 
that this rate of recruitment was because of time 
pressures, which were very intensive for the acute setting. 
Although roughly a third of patients chose not to be 
randomly assigned, we noted no evidence of recruitment 
bias compared with the observational studies done in the 
same recruiting network, which used very similar 
baseline clinical pro forma and had patients with very 
similar characteristics (80% had sputum and 15% had 
other lung disease).1 Our choice of antibiotic might have 
restricted eﬃ  cacy, but the chosen dose of amoxicillin 
eﬀ ectively treated more than 90% of all isolates in Europe. 
The size of the older age group restricted the power to 
assess a reduction in deterioration in illness. Similarly, 
some other clinical subgroups might beneﬁ t from 
amoxicillin. Poor adherence could have diminished 
eﬃ  cacy, but more than 90% of patients in both groups 
reported taking the study drugs by day 5, and adherence 
is probably better in a trial than in routine care.32
Our study provides further evidence for the long natural 
history of lower-respiratory-tract infections. In previous 
studies,1,9 most people had clinically signiﬁ cant symptoms 
n Original model with 
missing data
All patients with missing 
data resolved on day 1
All patients with missing 
data resolved on day 28
All patients with missing 
data unresolved on day 28
Eﬀ ect p Eﬀ ect p Eﬀ ect p Eﬀ ect p
Whole dataset 1799 1·06 0·229 1·06 0·237 1·05 0·316 1·05 0·311
Age 60 years or older 550 0·95 0·555 0·96 0·637 0·97 0·720 0·96 0·638
Age younger than 60 years 1249 1·12 0·071 1·11 0·101 1·08 0·163 1·10 0·130
Table 5: Eﬀ ect of diﬀ erent assumptions about missing data on hazard ratios of amoxicillin versus placebo for resolution of symptoms rated “moderately 
bad” or worse
See Online for appendix
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for more than a week before presentation and severe 
symptoms for about 7 days afterwards (and milder 
symptoms for even longer).
Neither duration of symptoms nor symptom severity 
was signiﬁ cantly aﬀ ected by amoxicillin. Symptom se verity 
was measured as the mean diary score for all symptoms 
during days 2–4 after the index consultation because this 
period is when symptoms are rated as the worst problem by 
patients. Before day 2, antibiotics will have had little chance 
to provide beneﬁ t and after day 4, although some symptoms 
remain “moderately bad” or worse, mean diary scores for all 
symptoms tend to be rated less than “moderately bad”.
Although new or worsening symptoms developed 
signiﬁ cantly less often in the amoxicillin than in the 
placebo group, the number needed to treat was high, and 
three patients only had to be admitted to hospital. The 
deﬁ nition of new or worsening symptoms used was 
useful and workable in previous studies of respiratory-
tract infection in the community.33 Because so few 
patients needed to be admitted to hospital, the outcomes 
eﬀ ectively represent symptom control. Our ﬁ ndings are 
consistent with those of a Cochrane review of anti biotics 
for acute bronchitis16 and consensus guidance,15 but 
suggest that amoxicillin is even less beneﬁ cial than was 
noted in the placebo-controlled trials in the Cochrane 
review (possibly because of diﬀ erences in setting and 
spectrum bias). Any moderate beneﬁ ts need to be 
balanced against the probable slight harms from 
treatment (number needed to harm was about 20 for 
rash, nausea, or diarrhoea in the amoxicillin group). The 
restricted beneﬁ t of antibiotics might partly be because, 
for most acute lower-respiratory-tract infections in 
primary care, bacterial pathogens can only be identiﬁ ed 
in a few patients.28,30 In view of the small numbers of 
patients who beneﬁ t from antibiotic treatment, the 
challenge is to identify these individuals.
Previous estimates of beneﬁ t of antibiotics in older 
patients have varied; one study of doxycycline showed a 
beneﬁ t,33 but another of amoxicillin did not.9 However, 
the numbers of patients included in these studies were 
small, and the CIs for the estimates of eﬀ ect were wide.
Our results suggest strongly that for older patients in 
whom pneumonia is not suspected, amoxicillin has very 
little eﬀ ect. However, severely ill older patients with 
several comorbidities are unlikely to have been 
approached to participate in the trial, so these ﬁ ndings 
should be interpreted cautiously and not extrapolated to a 
generally unwell older population.15
In conclusion, amoxicillin provides little symptomatic 
beneﬁ t for patients presenting in primary care who are 
judged to have clinically uncomplicated lower-respira tory-
tract infections. Any mild, short-term beneﬁ ts of antibiotic 
treatment should be balanced against the risks of side-
eﬀ ects and, in the long-term, of fostering resistance.
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Panel: Research in context
Systematic review
The authors of a Cochrane review16 searched the Cochrane Central Register of Controlled 
Trials (including the Acute Respiratory Infections Group’s specialised register), Medline 
(for studies published between 1966, and week 4 of August, 2010), and Embase (for 
studies published between 1974, and September, 2010) for randomised controlled trials 
of antibiotics in patients with acute bronchitis (including acute cough with or without 
sputum production). The main search terms used were “exp bronchitis”, “bronchit*.tw.”, 
“(bronchial adj2 infect*).tw”, “exp respiratory tract infections”, and “exp anti-bacterial 
agents”; the appendix contains a full list of terms used. The placebo-controlled studies 
identiﬁ ed in the review provide little evidence of important symptomatic outcomes; at 
follow-up, patients given antibiotics were less likely to have a cough than were those 
given placebo (risk ratio 0·64, 95% CI 0·49–0·85; number needed to treat 6), but these 
results came from only four studies23–26 with 275 participants in total. Patients given 
antibiotics were also less likely to have a night cough (0·67, 0·54–0·83; 7), but this ﬁ nding 
was noted in a population of only 538 participants. Numbers of patients were small for 
the outcomes of feeling unwell (n=435) or activity limitation (393). The review provided 
no data about the role of antibiotics in subgroups of patients—particularly the ﬁ t elderly.
Interpretation
Our trial is the largest study so far of the use of antibiotics in acute lower-respiratory-tract 
infection, and adds much to the placebo-controlled evidence noted in the Cochrane 
review, especially data for patients aged 60 years or older.16 Compared with placebo, 
amoxicillin did not signiﬁ cantly aﬀ ect the duration of symptoms rated “moderately bad” 
or worse in the ﬁ rst few days of infection, neither overall nor in patients older than 
60 years. Symptom severity also did not diﬀ er signiﬁ cantly between treatment groups. 
Amoxicillin prevented some patients from developing new or worse symptoms but the 
number needed to treat was high and matched by a similarly sized number needed to 
harm for side-eﬀ ects. Our data suggest, if anything, a smaller beneﬁ t from antibiotics for 
symptoms and a clearer estimate of harms than did the Cochrane review. Thus, unless 
pneumonia is suspected, antibiotics should not be prescribed for patients with acute 
lower-respiratory-tract infection.
Articles
www.thelancet.com/infection   Vol 13   February 2013 129
References
1 Butler C, Hood K, Verheij T, et al. Variation in antibiotic prescribing 
and its impact on recovery in patients with acute cough in primary 
care: prospective study in 13 countries. BMJ 2009; 338: b2242.
2 Her Majesty’s Stationery Oﬃ  ce, Oﬃ  ce of Population Census and 
Surveys. Morbidity statistics from general practice: fourth national 
study, 1991. London: HM Stationery Oﬃ  ce, 1994.
3 Petersen I, Johnson A, Islam A, Duckworth G, Livermore D, 
Hayward A. Protective eﬀ ect of antibiotics against serious 
complications of common respiratory tract infections: retrospective 
cohort study with the UK General Practice Research Database. BMJ 
2007; 335: 982.
4 Akkerman E, Van der Wouden J, Kuyvenhoven M, Dieleman J, 
Verheij T. Antibiotic prescribing for respiratory tract infections in 
Dutch primary care in relation to patient age and clinical entities. 
J Antimicrob Chemother 2004; 54: 1116–21.
5 Cornford CS. Why patients consult when they cough: a comparison 
of consulting and non-consulting patients. BJGP 1998; 48: 1751–54.
6 Kumar S, Little P, Britten N. Why do GPs prescribe antibiotics for 
sore throat? A grounded theory interview study of general 
practitioners. BMJ 2003; 326: 138.
7 Little P, Watson L, Morgan S, Williamson I. Antibiotic prescribing 
and admissions with major suppurative complications of 
respiratory tract infections: a data linkage study. Br J Gen Pract 
2002; 52: 187–93.
8 Price D, Honeybourne D, Little P, et al. Recent trends in GP 
antibiotic prescribing practice: a potential link to increased 
community-acquired pneumonia mortality. Respir Med 2004; 
98: 17–24.
9 Little P, Rumsby K, Kelly J, et al. Information leaﬂ et and antibiotic 
prescribing strategies for acute lower respiratory tract infection: 
a randomised controlled trial. JAMA 2005; 293: 3029–35.
10 Moore M, Little P, Rumsby K, et al. Eﬀ ect of antibiotic prescribing 
strategies and an information leaﬂ et on longer-term reconsultation 
for acute lower respiratory tract infection. Br J Gen Pract 2009; 
567: 728–34.
11 Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC 
project group. Outpatient antibiotic use in Europe and association 
with resistance: a cross-national database study. Lancet 2005; 
365: 579–87.
12 Gonzales R, Bartlett J, Besser R, et al. Principles of appropriate 
antibiotic use for treatment of uncomplicated acute bronchitis: 
background. Ann Emerg Med 2001; 37: 720–27.
13 Gonzales R, Sande M. Uncomplicated acute bronchitis. 
Ann Int Med 2000; 133: 981–89.
14 Gonzales R. A 65-year-old woman with acute cough illness and an 
important engagement. JAMA 2003; 20: 2710–08.
15 Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management 
of adult lower respiratory tract infections— full version. 
Clin Microbiol Infect 2011; 17 (suppl 6): E1–59.
16 Smith S, Fahey T, Smucny J, Becker L. Antibiotics for acute 
bronchitis. Cochrane Database Syst Rev 2009; 4: CD000245.
17 British Thoracic Society. British Thoracic Society Guidelines for the 
management of Community Acquired Pneumonia. Thorax 2001; 
56 (suppl 4): 1–64.
18 Flanders S, Stein J, Shochat G, et al. Performance of a bedside 
C-reactive protein test in the diagnosis of community-acquired 
pneumonia in adults with acute cough. Am J Med 2004; 116: 529–35.
19 Melbye H, Straume B, Aasebo U, Dale K. Diagnosis of pneumonia 
in adults in general practice. Relative importance of typical 
symptoms and abnormal chest signs evaluated against a 
radiographic reference standard. Scand J Prim Health Care 1992; 
10: 226–33.
20 Diehr P, Wood R, Bushyhead J. Prediction of pneumonia in 
outpatients with acute cough—a statistical approach. J Chronic Dis 
1984; 37: 21537–625.
21 Hopstaken R, Muris J, Knotternus J, Kester A, Rinkens P, Dinant G. 
Contributions of symptoms, signs, erythrocyte sedimentation rate, 
and C-reactive protein to a diagnosis of pneumonia in acute lower 
respiratory tract infection. Br J Gen Pract 2003; 53: 358–64.
22 Watson L, Little P, Williamson I, Moore M, Warner G. Validation 
study of a diary for use in acute lower respiratory tract infection. 
FamPract 2001; 18: 553–54.
23  Dunlay J, Reinhardt R, Roi LD. A placebo-controlled,double-blind 
trial of erythromycin in adults with acute bronchitis. J Fam Pract 
1987; 25: 137–41.
24 Hueston WJ. Albuterol delivered by metered-dose inhalerto treat 
acute bronchitis. J Fam Pract 1994; 39: 437–40.
25 Verheij T, Hermans J, Mulder J. Eﬀ ects of doxycycline in patients 
with acute cough and purulent sputum: a double blind placebo 
controlled trial. Br J Gen Pract 1995; 44: 400–04.
26 Williamson HA. A randomized controlled trial of doxycycline in the 
treatment of acute bronchitis. J Fam Pract 1984; 19: 481–86.
27 Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for 
community-acquired pneumonia diagnosed by general practitioners 
in the community. Respir Med 2000; 94: 422–27.
28 MacFarlane J, Holmes W, Gard P, et al. Prospective study of the 
incidence, aetiology and outcome of adult lower respiratory tract 
illness in the community. Thorax 2001; 56: 109–14.
29 Greene G, Hood K, Little P, et al. Towards clinical deﬁ nitions of 
lower respiratory tract infection (LRTI) for research and primary 
care practice in Europe: an international consensus study. 
Prim Care Respir J 2011; 20: 299–306.
30 Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. 
Prospective study of aetiology and outcome of adult 
lower-respiratory-tract infections in the community. Lancet 1993; 
341: 511–14.
31 Coenen S, Van Royen P, Michiels B, Denekens J. Optimizing 
antibiotic prescribing for acute cough in general practice: 
a cluster-randomized controlled trial. J Antimicrob Chemother 2004; 
54: 661–72.
32 Francis NA, Gillespie D, Nuttall J, et al. Antibiotics for acute cough: 
an international observational study of patient adherence in 
primary care. Br J Gen Pract 2012; 62: e429–37.
33 Hay A, Fahey T, Peters T, Wilson A. Predicting complications from 
acute cough in pre-school children in primary care: a prospective 
cohort study. Br J Gen Pract 2004; 54: 9–14.
